Rationalizing prescribing for oral and oesophageal candidiasis.
Taylor
C B
CB
Department of Genitourinary Medicine, King's Healthcare, London, UK.
Finlay
R
R
Richardson
C
C
Bunting
P
P
Welch
J
J
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000935:Antifungal Agents / Q000191:economics / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy*; D002180:Candidiasis, Oral / Q000188:drug therapy*; D016527:Drug Costs; D004935:Esophageal Diseases / Q000188:drug therapy*; D015725:Fluconazole / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D007654:Ketoconazole / Q000191:economics / Q000627:therapeutic use; D008485:Medical Audit; D017410:Practice Guidelines as Topic; D012189:Retrospective Studies
D000935:Antifungal Agents; D015725:Fluconazole; D007654:Ketoconazole